Continuous infusion of recombinant factor VIIa: continue or not?
Ewenstein
B M
BM
Hematology Division, Brigham & Women's Hospital, Boston, MA 02115, USA. bewenstein@partners.org
D016063:Blood Loss, Surgical / Q000517:prevention & control; D001792:Blood Platelets / Q000378:metabolism; D004334:Drug Administration Schedule; D017558:Elective Surgical Procedures; D005169:Factor VIII / Q000032:analysis; D015942:Factor VIIa / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006395:Hemarthrosis / Q000209:etiology / Q000601:surgery; D006406:Hematoma / Q000139:chemically induced; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
D011994:Recombinant Proteins; D005169:Factor VIII; D015942:Factor VIIa